The putative oncogene, CRNDE, is a negative prognostic factor in ovarian cancer patients

Oncotarget

Volumn 6, Issue 41, 2015, Pages 43897-43910

  Szafron, Lukasz Michal ^a   Balcerak, Anna ^a   Grzybowska, Ewa Anna ^a   Pienkowska Grela, Barbara ^a   Podgorska, Agnieszka ^a   Zub, Renata ^a   Olbryt, Magdalena ^b   Pamula Pilat, Jolanta ^b   Lisowska, Katarzyna M ^b   Grzybowska, Ewa ^b   Rubel, Tymon ^c   Dansonka Mieszkowska, Agnieszka ^a   Konopka, Bozena ^a   Kulesza, Magdalena ^a   Lukasik, Martyna ^a   Kupryjanczyk, Jolanta ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c WARSAW UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

CRNDE; Gene expression; Ovarian cancer; Prognostic factor; TP53

Indexed keywords

CYCLOPHOSPHAMIDE; PROTEIN P53; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; CRNDE RNA, HUMAN; LONG UNTRANSLATED RNA; PLATINUM DERIVATIVE; TAXOID; TUMOR MARKER;

ADULT; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; CRNDE GENE; FEMALE; FROZEN SECTION; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; ONCOGENE; OVARY CARCINOMA; PROTEIN AGGREGATION; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SPLICING DEFECT; AGED; DISEASE FREE SURVIVAL; DNA MICROARRAY; GENETICS; MIDDLE AGED; MORTALITY; OVARIAN NEOPLASMS; PROGNOSIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENES; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, LONG NONCODING; TAXOIDS;

EID: 84952890637     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6016     Document Type: Article

References (35)

1. Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A, Rinn JL. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 2011; 25:1915-27.
2. Szafron LM, Balcerak A, Grzybowska EA, Pienkowska-Grela B, Felisiak-Golabek A, Podgorska A, Kulesza M, Nowak N, Pomorski P, Wysocki J, Rubel T, Dansonka-Mieszkowska A, Konopka B, et al. The Novel Gene CRNDE Encodes a Nuclear Peptide (CRNDEP) Which Is Overexpressed in Highly Proliferating Tissues. PloS One. 2015; 10:e0127475.
3. Szafron L, Lisowska K, Rubel T, Sobiczewski P, Kupryjanczyk J. ING1, PTPN2, PCID2, VGLL1 and LOC388279 genes as potential prognostic markers in ovarian cancer. Int J Mol Med. 2009; 24:S40.
4. Nagaraj SH, Reverter A. A Boolean-based systems biology approach to predict novel genes associated with cancer: Application to colorectal cancer. BMC Syst Biol. 2011; 5:35.
5. Graham LD, Pedersen SK, Brown GS, Ho T, Kassir Z, Moynihan AT, Vizgoft EK, Dunne R, Pimlott L, Young GP, Lapointe LC, Molloy PL. Colorectal Neoplasia Differentially Expressed (CRNDE), a Novel Gene with Elevated Expression in Colorectal Adenomas and Adenocarcinomas. Genes Cancer. 2011; 2:829-40.
6. Wang Y, Wang Y, Li J, Zhang Y, Yin H, Han B. CRNDE, a long-noncoding RNA, promotes glioma cell growth and invasion through mTOR signaling. Cancer Lett [Internet]. 2015; Available from: http://dx.doi. org/10.1016/j.canlet.2015.03.027.
7. Zheng J, Li X-D, Wang P, Liu X-B, Xue Y-X, Hu Y, Li Z, Li Z-Q, Wang Z-H, Liu Y-H. CRNDE affects the malignant biological characteristics of human glioma stem cells by negatively regulating miR-186. Oncotarget. 2015; 6:25339-55. doi: 10.18632/oncotarget.4509.
8. Blagosklonny MV. Loss of function and p53 protein stabilization. Publ Online 14 Oct 1997 Doi101038sjonc1201374 [Internet]. 1997 [cited 2015 Sep 18]; 15. Available from: http://www.nature.com/onc/journal/v15/n16/abs/1201374a.html.
9. Blagosklonny MV. p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominantnegative effect. FASEB J. 2000; 14:1901-7.
10. Kupryjanczyk J, Szymanska T, Madry R, Timorek A, Stelmachow J, Karpinska G, Rembiszewska A, Ziolkowska I, Kraszewska E, Debniak J, Emerich J, Ulanska M, Pluzanska A, et al. Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen. Br J Cancer. 2003; 88: 848-54.
11. Kupryjanczyk J, Madry R, Plisiecka-Halasa J, Bar J, Kraszewska E, Ziolkowska I, Timorek A, Stelmachow J, Emerich J, Jedryka M, Pluzanska A, Rzepka-Gorska I, Urbanski K, et al. TP53 status determines clinical significance of ERBB2 expression in ovarian cancer. Br J Cancer. 2004; 91: 1916-23.
12. Felisiak-Golabek A, Rembiszewska A, Rzepecka IK, Szafron L, Madry R, Murawska M, Napiorkowski T, Sobiczewski P, Osuch B, Kupryjanczyk J, the Polish Ovarian Cancer Study Group (P. O. C. S. G). Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients. J Ovarian Res. 2011; 4:20.
13. Ellis BC, Molloy PL, Graham LD. CRNDE: A Long Non-Coding RNA Involved in CanceR, Neurobiology, and DEvelopment. Front Genet. 2012; 3:270.
14. Wahlstrom T, Arsenian Henriksson M. Impact of MYC in regulation of tumor cell metabolism. Biochim Biophys Acta [Internet]. 2014; Available from: http://dx.doi. org/10.1016/j.bbagrm.2014.07.004.
15. Ellis BC, Graham LD, Molloy PL. CRNDE, a long noncoding RNA responsive to insulin/IGF signaling, regulates genes involved in central metabolism. Biochim Biophys Acta. 2014; 1843:372-86.
16. Chen Y, Wu J-J, Lin X-B, Bao Y, Chen Z-H, Zhang C-R, Cai Z, Zhou J-Y, Ding M-H, Wu X-J, Sun W, Qian J, Zhang L, et al. Differential lncRNA expression profiles in recurrent gliomas compared with primary gliomas identified by microarray analysis. Int J Clin Exp Med. 2015; 8:5033-43.
17. Ziolkowska-Seta I, Madry R, Kraszewska E, Szymanska T, Timorek A, Rembiszewska A, Kupryjanczyk J. TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens. Gynecol Oncol. 2009; 112:179-84.
18. Ludwig AH, Murawska M, Panek G, Timorek A, Kupryjanczyk J. Androgen, progesterone, and FSH receptor polymorphisms in ovarian cancer risk and outcome. Endocr Relat Cancer. 2009; 16:1005-16.
19. Kupryjanczyk J. Why TP53 status does not associate with clinical endpoints in ovarian cancer: Facts and hypotheses. Gynecol Oncol. 2006; 100:5-7.
20. Huang GC, Hobbs S, Walton M, Epstein RJ. Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells. Br J Cancer. 2002; 86:1104-9.
21. Myrthue A, Rademacher BLS, Pittsenbarger J, Kutyba-Brooks B, Gantner M, Qian DZ, Beer TM. The iroquois homeobox gene 5 is regulated by 1,25-dihydroxyvitamin D3 in human prostate cancer and regulates apoptosis and the cell cycle in LNCaP prostate cancer cells. Clin Cancer Res Off J Am Assoc Cancer Res. 2008; 14:3562-70.
22. PE Biosystems. Sequence Detection Systems Quantitative Assay Design and Optimization [Internet]. Available from: http://www.gene-quantification.de/pe-realtimeoverview-2.pdf.
23. 1000 Genomes Project Consortium, Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, Gibbs RA, Hurles ME, McVean GA. A map of human genome variation from population-scale sequencing. Nature. 2010; 467:1061-73.
24. Creasman WJ. Announcement, FIGO stages 1988, revisions. Gynecol Oncol. 1989; 35:125-7.
25. Tavassoli FA, Devilee P. Pathology and genetics of tumours of the breast and female genital organs World Health Organisation classification of tumours. IARC Press Lyon. 2003;.
26. Barber HR, Sommers SC, Synder R, Kwon TH. Histologic and nuclear grading and stromal reactions as indices for prognosis in ovarian cancer. Am J Obstet Gynecol. 1975; 121:795-807.
27. Dansonka-Mieszkowska A, Ludwig AH, Kraszewska E, Kupryjanczyk J. Geographical variations in TP53 mutational spectrum in ovarian carcinomas. Ann Hum Genet. 2006; 70:594-604.
28. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981; 47:207-14.
29. Lisowska KM, Dudaladava V, Jarzab M, Huzarski T, Chmielik E, Stobiecka E, Lubinski J, Jarzab B. BRCA1-related gene signature in breast cancer: the role of ER status and molecular type. Front Biosci Elite Ed. 2011; 3:125-36.
30. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods San Diego Calif. 2001; 25:402-8.
31. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3:RESEARCH0034.
32. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol. 2007; 8:R19.
33. Wu Z, Irizarry RA, Gentleman R, Murillo FM, Spencer F. A model-based background adjustment for oligonucleotide expression arrays. J Am Stat Assoc. 2004; 99:909-917.
34. Affymetrix. GeneChip® Expression Analysis-Data Analysis Fundamentals. 2002.
35. Altman DG. Practical Statistics for Medical Research. Chapman and Hall; 1991.